{'fraction_non_alphanumeric': 0.03755868544600939, 'fraction_numerical': 0.014084507042253521, 'mean_word_length': 4.77027027027027, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Outcomes after definitive treatment for head and neck angiosarcoma

Head and neck angiosarcoma (HN‐AS) is a rare and aggressive, representing <1% of all head and neck malignancies. It is characterized by a high rate of local recurrence and poor 5‐year survival (10–54%). Australian data in this rare disease is lacking. We aim review the clinical outcomes of HN‐AS from two high volume head and neck cancer units in Australia.